“Global Clinical Trial Management System market forecast is expected to reach $4,805.6m by 2030” says new Visiongain report

17 March 2020
Pharma

Visiongain has launched a new pharma report Global Clinical Trial Management System Market.

The Global Market for Clinical Trial Management System is favoured by technological advancements and the rise of e-clinical platforms within clinical research organisations will continue to drive and take on more clinical trial projects. Continued market disruption by multiple industry forces such as advances in medicine, technology, and cost pressures will also allow now point solution vendors to distinguish themselves and their services over platform vendors. This dynamic will support ongoing diversity in the CTMS technology ecosystem even as the benefits of the CTMS platform continue to grow.

The lead analyst of the report commented "The clinical trials management system market is expected to witness a robust growth during the years of forecast owing to the rise in the number of clinical trials, rising investments in CTMS and advancements in technology. Clinical trial technology vendors have taken the pace of consolidating and incorporating technologies and resources into cloud-based e-clinical systems that support many clinical trial processes. Advanced technologies such as AI, better visualisations and analytics are enabling clients to unlock significant efficiencies in R&D. Having said this, many CROs are entering the CTMS space and increasingly developing their own solutions, this has led to talent poaching and increased competition on the market."

Leading companies featured in the report include Parexel Informatics Inc, Oracle, Medpace Holdings. Mednet Solutions, ERT Clinical, DataTRAK Internationals, Inc and many others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever